Identification of a novel four-lncRNA signature as a prognostic indicator in cirrhotic hepatocellular carcinoma

Linkun Ma 1, Cunliang Deng 1

1 Department of Infectious Diseases, The Affiliated Hospital of Southwestern Medical University, Luzhou, China

Corresponding Author: Cunliang Deng
Email address: dengcunl@swmu.edu.cn

Background. Many studies have shown that long noncoding RNAs (lncRNA) are closely associated with the occurrence and development of various tumors and have the potential to be prognostic markers. Moreover, cirrhosis is an important prognostic risk factors in patients with liver cancer. Some studies have reported that lncRNA-related prognostic models have been used to predict overall survival (OS) and recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC). However, no one has constructed a prognostic lncRNA model only in patients with cirrhotic HCC. Thus, it is necessary to screen novel potential lncRNA markers for improve the prognosis of cirrhotic HCC patients.

Methods. The probe expression profile dataset (GSE14520-GPL3921) from the Gene Expression Omnibus (GEO), which included 204 cirrhotic HCC samples, was reannotated and the lncRNA and mRNA expression dataset was obtained. The patients were randomly assigned to either the training set (n = 103) and testing set (n = 100). Univariate cox regression and the least absolute shrinkage and selection operator (LASSO) model were applied to screen lncRNAs linked to the OS of cirrhotic HCC in the training set. The lncRNAs having significant correlation with OS were then selected and the multivariate Cox regression model was implemented to construct the prognostic score model. Whether or not this model was related to RFS in the training set was simultaneously determined. The testing set was used to validate the lncRNA risk score model. A risk score based on the lncRNA signature was used for stratified analysis of different clinical features to test their prognostic performance. The prognostic lncRNA-related protein genes were identified by the co-expression matrix of lncRNA-mRNA, and the function of these lncRNAs was predicted through the enrichment of these co-expression genes.

Results. The signature consisted of four lncRNAs: AC093797.1, POLR2J4, AL121748.1 and AL162231.4. The risk model was closely correlated with the OS of cirrhotic HCC in the training cohort, with a hazard ratio (HR) of 3.650 (95% CI: 1.761–7.566) and log-rank P value of 0.0002. Moreover, this model also showed favorable prognostic significance for RFS in the training set (HR: 2.392, 95% CI: 1.374–4.164, log-rank P = 0.0015). The predictive performance of the four-lncRNA model for OS and RFS was verified in the testing set. Furthermore, the results of stratified analysis revealed that the four-lncRNA model was an independent factor in the prediction of OS and RFS of patients with clinical characteristics such as TNM (Tumor, Node, Metastasis system) stages I–II, Barcelona Clinic Liver Cancer (BCLC) stages 0–A, and solitary tumors in both the training set and testing set. The results of functional prediction showed that four lncRNAs may be potentially involve in multiple metabolic processes, such as amino acid, lipid, and glucose metabolism in cirrhotic HCC.
Identification of a novel four-lncRNA signature as a prognostic indicator in cirrhotic hepatocellular carcinoma

Linkun Ma¹, Cunliang Deng¹

¹ Department of infectious disease, Affiliated Hospital of Southwestern Medical University, NO.25 Taiping street, Luzhou, 646000, China.

Corresponding Author:
Cunliang Deng¹
Department of infectious disease, Affiliated Hospital of Southwestern Medical University, NO.25 Taiping street, Luzhou, 646000, China.
Email address: dengcunl64@vip.sina.com
ABSTRACT

Background. Many studies have shown that long noncoding RNAs (IncRNA) are closely associated with the occurrence and development of various tumors and have the potential to be prognostic markers. Moreover, cirrhosis is an important prognostic risk factors in patients with liver cancer. Some studies have reported that IncRNA-related prognostic models have been used to predict overall survival (OS) and recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC). However, no one has constructed a prognostic IncRNA model only in patients with cirrhotic HCC. Thus, it is necessary to screen novel potential IncRNA markers for improve the prognosis of cirrhotic HCC patients.

Methods. The probe expression profile dataset (GSE14520-GPL3921) from the Gene Expression Omnibus (GEO), which included 204 cirrhotic HCC samples, was reannotated and the IncRNA and mRNA expression dataset was obtained. The patients were randomly assigned to either the training set (n = 103) and testing set (n = 100). Univariate cox regression and the least absolute shrinkage and selection operator (LASSO) model were applied to screen IncRNAs linked to the OS of cirrhotic HCC in the training set. The IncRNAs having significant correlation with OS were then selected and the multivariate Cox regression model was implemented to construct the prognostic score model. Whether or not this model was related to RFS in the training set was simultaneously determined. The testing set was used to validate the IncRNA risk score model. A risk score based on the IncRNA signature was used for stratified analysis of different clinical features to test their prognostic performance. The prognostic IncRNA-related protein genes were identified by the co-expression matrix of IncRNA -mRNA, and the function of these IncRNAs was predicted through the enrichment of these co-expression genes.

Results. The signature consisted of four IncRNAs: AC093797.1, POLR2J4, AL121748.1, and AL162231.4. The risk model was closely correlated with the OS of cirrhotic HCC in the training cohort, with a hazard ratio (HR) of 3.650 (95% CI: 1.761–7.566) and log-rank P value of 0.0002. Moreover, this model also showed favorable prognostic significance for RFS in the training set (HR: 2.392, 95% CI: 1.374–4.164, log-rank P = 0.0015). The predictive performance of the four-IncRNA model for OS and RFS was verified in the testing set. Furthermore, the results of stratified analysis revealed that the four-IncRNA model was an independent factor in the prediction of OS and RFS of patients with clinical characteristics such as TNM (Tumor, Node, Metastasis system) stages I–II, Barcelona Clinic Liver Cancer (BCLC) stages 0–A, and solitary tumors in both the training set and testing set. The results of functional prediction showed that four IncRNAs may be potentially involve in multiple metabolic processes, such as amino acid, lipid, and glucose metabolism in cirrhotic HCC.
INTRODUCTION

Worldwide, liver cancer remains among the top six prevalent carcinomas among males and females from Global Cancer Statistics with an estimated 841,080 new cases and 781,631 deaths occurring in 2018 (International Agency for Research on Cancer, http://gco.iarc.fr/today/fact-sheets-cancers). According to the US centers for disease control and prevention, the mortality of liver cancer rose by 25 percent (from 5.3 per 100,000 to 6.6 per 100,000) between 2006 and 2015. (Centers for Disease Control and Prevention, 2018). Despite the existing treatment methods, such as hepatectomy, liver transplantation, radiofrequency ablation, embolization therapy, and molecule-targeted chemotherapy, high mortality and recurrence rates of liver cancer, fundamentally, have not been changed, and new interventions to improve the poor prognosis for patients with liver cancer is in continuing demand (Siegel, Miller & Jemal, 2018).

The stratified management of patients with hepatocellular carcinoma (HCC) according to specific clinical characteristics (e.g., using the Barcelona Clinic Liver Cancer staging system) has improved the prognosis of patients (Villanueva, Hernandez-Gea & Llovet, 2013). Among the various pathological types of liver cancer, HCC is the most common, accounting for about 80% of all cases (DeSantis et al., 2014). The occurrence of HCC is closely related to liver fibrosis. Studies have reported that 80–90% of patients with HCC present liver fibrosis or cirrhosis (El-Serag, 2011). A recent meta-analysis of studies in cirrhotic patients with five liver diseases (hepatitis B, hepatitis C, primary biliary cholangitis, autoimmune hepatitis, and non-alcoholic steatohepatitis) showed that the incidence of liver cancer is significantly increased when liver disease develops into cirrhosis, indicating that cirrhosis is one of the crucial risk factors for HCC (Tarao et al., 2019). Patients with liver cancer, with or without cirrhosis, show different clinical characteristics, including differences in tumor size and prognostic factors (Techathuvanan et al., 2015). With the development of bioinformatics, many genomic biomarkers, including lncRNAs, have been explored. Three circulating lncRNAs, LINC00152, RP11-160H22.5 and XLOC014172, were found to be candidate biomarkers for diagnosis for hepatocellular carcinoma (Yuan et al., 2017). Hu et al.'s meta-analysis showed that lncRNAs are correlated with the biological characteristics of gastric cancer, which may be a potential screening tool for the diagnosis of gastric cancer (Hu et al., 2017a). Hu et al confirmed that lncRNA-SVUGP2 expression in hepatocellular carcinoma tissues was associated with patient prognosis (Hu et al., 2017b). In addition, some lncRNAs have been found in serum to be biomarkers for tumor diagnosis. For instance, GIHCG has been found to be biomarkers for serum diagnosis of cervical cancer (Zhang et al., 2019). The lncRNAs are a type of noncoding RNAs longer than 200 nucleotides, which play various important roles in malignant tumors (Ma et al., 2017). The lncRNAs reportedly play a role in various biological processes, including cell proliferation, apoptosis, metastasis, and microvascular changes, and exhibit stem cell-like properties (Yuan et al., 2012; Wang et al., 2014; Cui et al., 2015; Ma et al., 2016). Several studies have demonstrated that lncRNAs contribute to the stratification of prognosis for patients with liver cancer (Liao et al., 2018; Zhao et al., 2018; Gu et al., 2018). For example, Yan et al stratified the prognosis of HCC based on the seven-lncRNA signature, and the overall survival of
the high-risk group was significantly lower than that of the low-risk group (Yan et al., 2019).

Currently, a lncRNAs signature is absent for stratification of prognosis in patients with cirrhotic hepatocellular carcinoma. Some studies indicate that the knockdown of lncRNA SUMO1P3 can inhibit the growth and invasion of hepatocellular carcinoma and enhance its radiotherapy sensitivity (Zhou et al., 2019). This suggests that lncRNA can be a potential target for the treatment of hepatocellular carcinoma. Therefore, this study aims to further explore the prognostic biomarkers of the pathogenesis of cirrhotic HCC by analyzing microarray, and to provide some potential targets for the biological treatment of HCC.

**MATERIALS & METHODS**

**Data availability statement**

The following information was supplied regarding data availability:

Raw data were generated in the study. All original data in this study were downloaded from the public databases GEO (https://www.ncbi.nlm.nih.gov/geo/).

For the four-lncRNA signature identification, we used GSE14520 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520).

**Probe reannotation and preparation of gene expression profiles**

The GSE14520 expression profiles and clinical information analyzed in this study were derived from the GEO database (https://www.ncbi.nlm.nih.gov/geo/). To consider the expression and function of lncRNAs in the probes of HCC, the probes of the Affymetrix HT Human Genome U133A Array were reannotated to obtain the lncRNA and mRNA co-expression matrix using the following steps. Firstly, the Affymetrix HT Human Genome U133A Array probe was mapped to the gencode annotation file (Gencode.v29. transcripts, FASTA format,09/27/2018). Information about specific probe set annotation included the probe set ID, Ensemble ID, probe sequence, among other data. Secondly, the probe sets that were allocated to the Ensemble gene IDs in the gencode annotations were acquired. Human coding and noncoding gene annotation files (Homo_sapiens.GRCh38.95.chr.gtf.gz, GTF format, 11/25/2018) from the Ensemble database were used to extract the matching information of gene ID and gene symbol. The Ensemble IDs of the probes were then assigned gene IDs, and only those annotated as “protein coding,” “antisense,” “sense intronic,” “bidirectional promoter lncRNA,” “lincRNA,” “non-coding,” “macro lncRNA,” “processed transcript,” “3′ overlapping ncRNA,” and “sense overlapping” were retained. In addition, probes that corresponded to multiple Ensemble IDs were removed. Finally, 12 096 protein-coding transcripts and 610 lncRNA transcripts (different probe IDs may have corresponded to the same transcript) were reannotated.

The GSE14520 probe expression profile from the GEO database was annotated by the reannotated GPL3921 (Affymetrix HT Human Genome U133A Array), including 225 tumor samples and 220 paired non-tumor tissue samples. Among them, the survival information of 203
patients was obtained from the dataset of GSE14520. If multiple probes corresponded to the same gene, the final expression of the gene was determined by the arithmetic mean of multiple probes. The gene expression profile of GSE14520 was normalized by the limma software package. Normalization was performed using the normalizeBetweenArrays function in the limma package (Bolstad et al., 2003). The inclusion criteria were as follows: pathologically confirmed HCC tissues, and patients with liver cirrhosis, and complete follow-up survival information, including overall survival (OS) and recurrence-free survival (RFS). Exclusion criteria included non-tumor tissues, absence of histological examination results, pathological results indicating cholangiocarcinoma, hepatocellularcholangiocarcinoma, or secondary liver cancer, and missing OS or RFS information. It contained 225 HCC tissue samples and 220 adjacent non-tumor tissue samples. Out of 225 HCC samples, 221 with complete follow-up information (Survival status, Survival time, recurrence status and recurrence-free time) were included in the microarray. Of these 221 patients, 203 have cirrhosis. All 203 participants were patients who underwent radical resection of HCC at the Liver Cancer Institute and Zhongshan Hospital (Fudan University, Shanghai, China) between 2002 and 2003. Of the 203 participants, 177 were male and 26 were female. The mean age of all patients in the dataset was 51.3 years. Regarding the TNM stage of HCC, 153 of the 203 patients were in stage I or II, and 48 were in stage III. Only 2 patients had no documented cancer stage.

Data and clinical characteristics

All 204 patients with liver cancer from the GSE14520 of the GEO database had complete survival information and were included in the study. These patients were randomly divided into the training set (n = 103) and testing set (n = 100) using the R caret software package. The clinical parameters of the two groups of patients are presented in Table 1.

Construction of lncRNA expression-based prognostic signature

Univariate Cox regression analysis was used to screen for significant prognostic lncRNAs in the training set. A P value < 0.05 was selected as the threshold for candidate lncRNAs. Candidate prognostic lncRNAs were further reduced by least absolute shrinkage and selection operator (LASSO) regression. The principle of LASSO regression is to eliminate some variables through penalty rules, and ultimately leave all potential predictors with a non-zero coefficient (Gao, Kwan & Shi, 2010). The penalty argument lambda was determined by the cross-validation method using the R glmnet software package. Lambda.min, the lambda value corresponding to the minimum value of the cross-validation error mean, was identified to determine the potential prognostic lncRNAs (Tibshirani, 1997). Each “significant” lncRNA obtained in the above steps were then fitted into a multivariate Cox regression model, and lncRNAs associated with independent prognostic criteria were selected. The prognostic risk formulas were formed, based on the expression level of those remaining eligible lncRNAs multiplied by the multivariate Cox
regression coefficient. Risk scores for each sample were calculated using the risk score formula, and patients were divided into high-risk and low-risk groups based on the median risk score of the training cohort as the cutoff value. The same formulas and cutoff values were used to calculate the risk score and risk grouping for patients in the testing set (Zhao et al., 2018). A Kaplan–Meier survival curve and log-rank test were used to analyze the overall survival (OS) and recurrence-free survival (RFS) of patients in the high-risk and low-risk groups in both the training and testing set (Li et al., 2018). A receiver operating characteristic (ROC) curve plotted with the survivalROC software package (version 1.0.3) was adopted to evaluate the specificity and sensitivity of the survival prediction (Heagerty, Lumley & Pepe, 2000). Both ROC and Kaplan–Meier survival curves were constructed with the R studio software (version 3.5.1). A P value < 0.05 was deemed statistically significant.

Functional enrichment analyses

In order to obtain the lncRNA-mRNA co-expression pair, we conducted Pearson correlation analyses between the four lncRNAs identified and the expression profile of the protein-coding genes of the discovery set. The protein-coding genes with a correlation coefficient > 0.4 and P < 0.001 were recognized as the four lncRNA-associated genes. The correlated mRNAs were evaluated by functional enrichment analysis to explore the functions of the four prognostic lncRNAs using the clusterProfiler (version 3.10.1) and org.Hs.eg.db (version 3.7.0) package (Yu et al., 2012). Significantly enriched Gene Ontology (GO) terms and Kyoko Encyclopedia of Genes and Genomes (KEGG) pathways with a P value < 0.05 and q value < 0.05 were visualized using the R studio (version 3.5.1) software.

Statistical analysis

The prognostic ability of the four-lncRNA signature under different clinical parameters was analyzed by Kaplan–Meier survival analysis, to determine which population is most suited for this prognostic model. The survival curve was drawn using the R survminer software package. Statistical analyses were conducted using the SPSS software (version 24.0) and R studio (version 3.5.1).

RESULTS

Construction of risk prognostic scoring system in the training set

The exploration process of this study is shown in figure 1. Firstly, 610 lncRNAs were initially screened in the training set (Table S1), and 35 potential OS-related lncRNAs were obtained by a univariate Cox risk regression model (Table S2) (P < 0.05). The remaining lncRNAs were
further selected using LASSO regression analysis, and cross-validation was used to select the
penalty parameters (Fig. 2A–B). Five lncRNAs were identified by lambda.min value (Table S3).
The lncRNAs obtained in the above steps were inserted into the multivariate Cox regression
model. The expression values of four independent prognostic lncRNAs (P value < 0.05) and their
correlation coefficients in a multivariate regression model were then used to construct prognostic
signatures. Detailed information and the significance of survival prediction by the four lncRNAs
are presented in Table 2.
Risk score = (expression quantity of AC093797.1 × -0.4818) + (expression quantity of
AL121748.1 × 0.4404) + (expression quantity of AL162231.4 × 1.2845) + (expression quantity
of POLR2J4 × -1.5170).
The risk score formula in the training set was used to calculate the risk score of each patient. The
median score for all patients in the training set was deemed the cutoff value, and facilitated the
division of patients into a high-risk group (n = 51) and low-risk group (n = 52) (Table S4).
Patients of the training group were ranked in ascending order of risk score (Fig. 3A). Moreover,
the expression profiles of the four lncRNAs were plotted on a heatmap (Fig. 3B). In addition, a
scatter plot was constructed to show the OS status and recurrence status of patients (Fig. 3C–D).
The high-risk group had a worse prognosis than the low-risk group in terms of OS and RFS. The
prognosis of the high-risk group was compared with that of the low-risk group using Kaplan–
Meier curve analysis. The results showed that the OS (HR: 3.650, 95% CI: 1.761–7.566, log-
rank P = 0.0002) and RFS (HR: 2.392, 95% CI: 1.374–4.164, log-rank P = 0.0015) of high-risk
patients were significantly lower than those of low-risk patients (Fig. 4A–B). Furthermore,
according to the four-lncRNA signature, the area under the curve of time-dependent ROC
analysis of the 5-year OS and RFS predicted in the training set reached 0.839 and 0.715,
respectively (Fig. 4C–D).

Prognostic performance of the four-lncRNA signature in the testing set
To further assess the prognostic significance of the four-lncRNA signature, internal validation
was performed in a group of 100 patients from the testing set. The established formula for the
training set was used to calculate the patient risk score for the testing set. The same cutoff value
used for the training set was also used to divide the testing set into high-risk (n = 44) and low-
risk cohorts (n = 56) (Table S5). Kaplan–Meier survival analysis was also performed in the
testing set. As shown in Fig. 5A–B, the four-lncRNA signature showed favorable prognostic
value in differentiating the risk stratification of death (HR: 2.475, 95% CI: 1.347–4.547, log-rank
P = 0.0015) and recurrence (HR: 2.245, 95% CI: 1.349–3.736, log-rank P = 0.0014) in patients.
The ROC curve was used to analyze the predictive power of risk models in the validation group
for 5-year OS (Fig. 5C) and RFS (Fig. 5D). The OS and RFS of patients in the testing group
were plotted (Fig. 5E–F). These results suggested that the four-lncRNA signature in patients with
cirrhotic HCC has considerable potential in predicting OS and RFS.
Stratification analysis

To explore the different clinical characteristics for which the four-lncRNA model is applicable, we conducted subgroup analyses of OS and RFS on patients of both the training set and testing set. The risk grouping principle was based on the median four-lncRNA risk score of the training set. Subgroup analyses combining the training and validation sets showed that the risk score model based on the four-lncRNA signature was more appropriate for patients with the following characteristics: BCLC stages 0–A, solitary tumors, and Tumor, Node, Metastasis system (TNM) stages I–II. The results of subgroup analyses of the OS and RFS are shown in Tables 3 and 4, respectively. Kaplan–Meier curves were constructed for both high-risk and low-risk patients with TNM stages I–II, solitary tumors, and BCLC stages 0–A, to analyze the prognostic value of risk models in OS (Fig. 6A–F) and RFS of cirrhotic HCC (Fig. 7A–F). Among the patients with the three aforementioned clinical characteristics, the OS (Fig. 6A ($P = 0.00021$), Fig. 6B ($P = 0.0015$), Fig. 6C ($P = 0.0012$), Fig. 6D ($P = 0.0043$), Fig. 6E ($P = 0.00033$), and Fig. 6F ($P = 0.0019$)) and RFS (Fig. 7A ($P = 0.0018$), Fig. 7B ($P = 0.0019$), Fig. 7C ($P = 0.0028$), Fig. 7D ($P = 0.00061$), Fig. 7E ($P = 0.0023$), and Fig. 7F ($P = 0.0018$)) of high-risk patients were worse than those of low-risk patients.

Functional enrichment analyses

Firstly, the co-expression matrix of the four lncRNAs and 12,100 protein-coding genes were extracted from 204 patients with tumor tissue gene expression profile data from GSE14520. The correlation between lncRNAs and protein-coding genes was analyzed. The significantly correlated protein-coding genes (Pearson coefficient > 0.4, $P < 0.001$) were used for GO analysis (Table S6) and KEGG enrichment analysis (Table S7) to determine the potential mechanism of the four lncRNAs in regulating HCC. Functional enrichment analysis was conducted with the R org.Hs.eg.db (version 3.7.0) and clusterProfiler (version 3.10.1) package (Yu et al., 2012). The first 25 significant GO terms ($P < 0.05$, $q < 0.05$) (Fig. 8A) and first 25 significant KEGG pathways ($P < 0.05$, $q < 0.05$) (Fig. 8B) were charted using the R software (version 3.5.1). The results of GO analysis revealed that four-lncRNA-related functions showed enrichment in protein-coding genes involved in a large group of GO terms, including those associated with transmembrane transport, redox reactions, and fatty acid metabolism. Furthermore, KEGG analysis showed significant associations with a series of enriched pathways, including the peroxisome proliferator-activated receptor (PPAR) signaling pathway, amino acid metabolism, fatty acid metabolism, and chemical carcinogenesis.

DISCUSSION

Currently, the popularity and wide application of gene microarray technology has presented considerable convenience to researchers who attempt to develop prognostic biomarkers of tumors. A large number of studies have confirmed that lncRNAs play an indispensable role in
the proliferation, metastasis, metabolic regulation, and drug resistance of various tumors (Pan et al., 2016; Kia et al., 2019; Liu et al., 2019; Schwarzenbacher et al., 2019; Zheng et al., 2019). Therefore, their performance in determining the prognosis of various tumors has drawn widespread interest. The significance of prognostic signatures based on lncRNA expression has been demonstrated in various tumors, including those of head and neck squamous cell carcinoma (Cao et al., 2017), gastric cancer (Song et al., 2017), breast cancer (Li et al., 2018), cervical squamous cell carcinoma (Mao et al., 2018), and HCC (Song et al., 2017). For example, RGMB-AS1 plays an anti-tumor role by regulating a variety of biological processes in HCC cells (Sheng et al., 2018). Many unknown functional lncRNAs are yet to be explored. Moreover, cirrhosis of the liver is often associated with liver cancer, and more than 80% of patients with liver cancer have cirrhosis (Affo, Yu & Schwabe, 2017). To explore new prognostic lncRNAs in patients with cirrhotic HCC, patients with HCC and liver cirrhosis were included as subjects of the present study, and the lncRNA expression profile and clinical information were extracted from the GEO database for a comprehensive analysis.

We developed a prognosis formula for cirrhotic HCC based on the four lncRNAs, including AC093797.1, AL121748.1, AL162231.4, and POLR2J4, and verified it in the testing set. Patients were divided into high-risk and low-risk groups according to the prognostic signature score. Kaplan–Meier analysis confirmed that the four-lncRNA signature has favorable OS and RFS prediction ability and could be considered a new prognostic biomarker. Stratified analysis was used to assess the prognostic performance of this signature in patients with different clinical characteristics. We found that the four-lncRNA signature was significantly correlated with OS and RFS in patients with specific characteristics, including TNM stages I–II, solitary tumors, and BCLC stages 0–A. The selection of appropriate treatment methods is of prime importance for improving the prognosis of patients with early liver cancer (Vitale et al., 2017). In addition, the results of a relevant meta-analysis showed that liver transplantation had a higher OS rate and lower recurrence rate than hepatectomy among patients with liver cancer and Child-Turcotte-Pugh class A cirrhosis (Zheng et al., 2014). Although liver transplantation can achieve a better prognosis, it is especially important to be selective in determining the candidates for this procedure, owing to a shortage of donor livers. Our four-lncRNA label can help clinicians to predict and stratify the prognosis of patients after surgery, and implement reasonable treatment programs.

Among the four lncRNAs, AC093797.1 and POLR2J4 were risk factors for liver cancer, whereas the other two were protective factors (AL121748.1 and AL162231.4). With the exception of POLR2J4, the lncRNAs were deemed prognostic markers of liver cancer for the first time, to our knowledge. Their function in HCC is unclear, and we determined their potential biological function through function enrichment analysis of related proteins. The GO enrichment analysis showed that the four lncRNA-related protein-coding genes were mainly involved in lipid metabolism and glycolysis, including fatty acid ligase activity, long-chain fatty acid-CoA ligase activity, oxidoreductase activity, and CoA ligase activity, among other processes. The KEGG pathway analysis showed that most genes were enriched in fatty acid and amino acid
metabolism. This indicates that the four lncRNAs may be potentially involved in tumorigenesis and the development of tumors through the regulation of metabolism. At present, tumor metabolism is one of the more popular topics in tumor research. Some studies have reported that lncRNAs can affect tumor metabolism through a variety of methods, such as by regulating oncogenes, tumor suppressor factors, and crucial transcription factors to affect tumor growth (Liu et al., 2019). Thus, lncRNAs are expected to be targets for future tumor treatment. The specific mechanism of the four lncRNAs in the present study in the regulation of tumor metabolism still needs to be further clarified in cell and animal experiments.

This study is a preliminary study that explored the prognosis of cirrhotic HCC. The data of only a single liver cancer cohort were included in the GEO database that was used to develop and verify the lncRNA signature. In addition, an independent external validation set of larger samples to verify the reliability of the model is lacking. Moreover, further experimental studies to verify the potential functions of the four lncRNAs are also lacking. Nevertheless, the four-lncRNA signature developed, based on the expression of lncRNA from the GEO database, has the potential to become a new and highly effective biomarker for patients with cirrhotic HCC. The present study lays the foundation for further exploration of prognostic markers in patients with early HCC.

CONCLUSIONS

In summary, we identified four potential lncRNAs biomarkers associated with prognosis in cirrhotic HCC, and constructed a risk score model. Patients in the high-risk group had lower overall survival and relapse-free survival than those in the low-risk group. Based on stratification analysis, the prognostic risk model might have ability to predict OS and RFS in cirrhotic HCC patients with BCLC stages 0–A, solitary tumors, and Tumor, Node, Metastasis system (TNM) stages I–II. Moreover, the four new lncRNAs identified could be used as potential therapeutic targets.

REFERENCES

Affo, S., Yu, L.X., and Schwabe, R.F. 2017. The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer. ANNUAL REVIEW OF PRATHOLOGY 12:153-186. doi:10.1146/annurev-pathol-052016-100322

Bolstad, B.M., Irizarry, R.A., Astrand, M., and Speed, T.P. 2003. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. BIOINFORMATICS 19:185-193.

Cao, W., Liu, J.N., Liu, Z., Wang, X., Han, Z.G., Ji, T., Chen, W.T., and Zou, X. 2017. A three-lncRNA signature derived from the Atlas of ncRNA in cancer (TANRIC) database predicts the survival of patients with head and neck squamous cell carcinoma. ORAL ONCOLOGY 65:94-101. doi:10.1016/j.oraloncology.2016.12.017
Cui, M., Xiao, Z., Wang, Y., Zheng, M., Song, T., Cai, X., Sun, B., Ye, L., and Zhang, X. 2015. Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway. CANCER RESEARCH 75:846-857. doi:10.1158/0008-5472.CAN-14-1192

DeSantis, C.E., Lin, C.C., Mariotto, A.B., Siegel, R.L., Stein, K.D., Kramer, J.L., Alteri, R., Robbins, A.S., and Jemal, A. 2014. Cancer treatment and survivorship statistics, 2014. CA: A CANCER JOURNAL FOR CLINICIANS 64:252-271. doi:10.3322/caac.21235

El-Serag, H.B. 2011. Hepatocellular carcinoma. NEW ENGLAND JOURNAL OF MEDICINE 365:1118-1127. doi:10.1056/NEJMra1001683

Gao, J., Kwan, P.W., and Shi, D. 2010. Sparse kernel learning with LASSO and Bayesian inference algorithm. NEURAL NETWORKS 23:257-264. doi:10.1016/j.neunet.2009.07.001

Heagerty, P.J., Lumley, T., and Pepe, M.S. 2000. Time-dependent ROC curves for censored survival data and a diagnostic marker. BIOMETRICS 56:337-344.

Hu, Q.Y., Zhao, Z.Y., Li, S.Q., Li, L., and Li, G.K. 2017a. A meta-analysis: The diagnostic values of long non-coding RNA as a biomarker for gastric cancer. MOLECULAR AND CLINICAL ONCLOGY 6:846-852. 10.3892/mco.2017.1227

Hu, J., Song, C., Duan, B., Zhang, X., Li, D., Zhu, L., and Gao, H. 2017b. LncRNA-SVUGP2 suppresses progression of hepatocellular carcinoma. ONCOTARGET 8:97835-97850. 10.18632/oncotarget.18279

Gu, J., Zhang, X., Miao, R., Ma, X., Xiang, X., Fu, Y., Liu, C., Niu, W., and Qu, K. 2018. A three-long non-coding RNA-expression-based risk score system can better predict both overall and recurrence-free survival in patients with small hepatocellular carcinoma. AGING (ALBANY NY) 10:1627-1639. 10.18632/aging.101497

Kia, V., Mortazavi, Y., Paryan, M., Biglari, A., and Mohammadi-Yeganeh, S. 2019. Exosomal miRNAs from highly metastatic cells can induce metastasis in non-metastatic cells. LIFE SCIENCES 220:162-168. doi:10.1016/j.lfs.2019.01.057

Li, J., Wang, W., Xia, P., Wan, L., Zhang, L., Yu, L., Wang, L., Chen, X., Xiao, Y., and Xu, C. 2018. Identification of a five-lncRNA signature for predicting the risk of tumor recurrence in patients with breast cancer. INTERNATIONAL JOURNAL OF CANCER 143:2150-2160. doi:10.1002/ijc.31573

Liao, X., Yang, C., Huang, R., Han, C., Yu, T., Huang, K., Liu, X., Yu, L., Zhu, G., Su, H., Wang, X., Qin, W., Deng, J., Zeng, X., Ye, X., and Peng, T. 2018. Identification of Potential Prognostic Long Non-Coding RNA Biomarkers for Predicting Survival in Patients with Hepatocellular Carcinoma. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY 48:1854-1869. doi:10.1159/000492507

Liu, H., Luo, J., Luan, S., He, C., and Li, Z. 2019. Long non-coding RNAs involved in cancer metabolic reprogramming. CELLULAR AND MOLECULAR LIFE SCIENCES 76:495-504. doi:10.1007/s00018-018-2946-1

Ma, Y., Huang, D., Yang, F., Tian, M., Wang, Y., Shen, D., Wang, Q., Chen, Q., and Zhang, L. 2016. Long Noncoding RNA Highly Upregulated in Liver Cancer Regulates the Tumor Necrosis Factor-alpha-Induced Apoptosis in Human Vascular Endothelial Cells. DNA AND CELL BIOLOGY 35:296-300. doi:10.1089/dna.2015.3203

Ma, Z., Huang, H., Xu, Y., He, X., Wang, J., Hui, B., Ji, H., Zhou, J., and Wang, K. 2017. Current advances of long non-coding RNA highly upregulated in liver cancer in human tumors. ONCOTARGETS AND THERAPY 10:4711-4717. doi:10.2147/OTT.S136915

Mao, X., Qin, X., Li, L., Zhou, J., Zhou, M., Li, X., Xu, Y., Yuan, L., Liu, Q.N., and Xing, H.
2018. A 15-long non-coding RNA signature to improve prognosis prediction of cervical squamous cell carcinoma. *Gynecologic Oncology* 149:181-187.
doi:10.1016/j.ygyno.2017.12.011

Pan, J., Li, X., Wu, W., Xue, M., Hou, H., Zhai, W., and Chen, W. 2016. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. *Cancer Letters* 382:64-76. doi:10.1016/j.canlet.2016.08.015

Schwarzenbacher, D., Klec, C., Pasculli, B., Cerk, S., Rinner, B., Karbiener, M., Ivan, C., Barbano, R., Ling, H., Wulf-Goldenberg, A., Stanzer, S., Rinnerthaler, G., Stoeger, H., Bauernhofer, T., Haybaeck, J., Hoefler, G., Jahn, S.W., Parrella, P., Calin, G.A., and Pichler, M. 2019. MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors. *Breast Cancer Research* 21:20. doi:10.1186/s13058-019-1104-5

Sheng, N., Li, Y., Qian, R., and Li, Y. 2018. The clinical significance and biological function of lncRNA RGMB-AS1 in hepatocellular carcinoma. *Biomedicine & Pharmacotherapy* 98:577-584. doi:10.1016/j.biopha.2017.12.067

Siegel, R.L., Miller, K.D., and Jemal, A. 2018. Cancer statistics, 2018. *CA: A Cancer Journal for Clinicians* 68:7-30. doi:10.3322/caac.21442

Song, P., Jiang, B., Liu, Z., Ding, J., Liu, S., and Guan, W. 2017. A three-lncRNA expression signature associated with the prognosis of gastric cancer patients. *Cancer Medicine* 6:1154-1164. doi:10.1002/cam4.1047

Tibshirani, R. 1997. The lasso method for variable selection in the Cox model. *Statistics in Medicine* 16:385-395.

Villanueva, A., Hernandez-Gea, V., and Llovet, J.M. 2013. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. *Nature Reviews Gastroenterology & Hepatology* 10:34-42. doi:10.1038/nrgastro.2012.199

Wang, F., Yuan, J.H., Wang, S.B., Yang, F., Yuan, S.X., Ye, C., Yang, N., Zhou, W.P., Li, W.L., Li, W., and Sun, S.H. 2014. Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing Nop2. *Hepatology* 60:1278-1290. doi:10.1002/hep.27239

Yu, G., Wang, L.G., Han, Y., and He, Q.Y. 2012. ClusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS: A Journal of Integrative Biology* 16:385-395.
Yuan, S.X., Yang, F., Yang, Y., Tao, Q.F., Zhang, J., Huang, G., Yang, Y., Wang, R.Y., Yang, S., Huo, X.S., Zhang, L., Wang, F., Sun, S.H., and Zhou, W.P. 2012. Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients' poor recurrence-free survival after hepatectomy. *HEPATOLOGY* 56:2231-2241. doi:10.1002/hep.25895

Yuan, W., Sun, Y., Liu, L., Zhou, B., Wang, S., and Gu, D. 2017. Circulating LncRNAs Serve as Diagnostic Markers for Hepatocellular Carcinoma. *CELLULAR PHYSIOLOGY AND BIOCHEMISTRY* 44:125-132. 10.1159/000484589

Zhang, X., Mao, L., Li, L., He, Z., Wang, N., and Song, Y. 2019. Long noncoding RNA GIHCG functions as an oncogene and serves as a serum diagnostic biomarker for cervical cancer. *JOURNAL OF CANCER* 10:672-681. 10.7150/jca.28525

Zhao, Q.J., Zhang, J., Xu, L., and Liu, F.F. 2018. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma. *WORLD JOURNAL OF GASTROENTEROLOGY* 24:3426-3439. doi:10.3748/wjg.v24.i30.3426

Zheng, Y., Lu, S., Xu, Y., and Zheng, J. 2019. Long non-coding RNA AGAP2-AS1 promotes the proliferation of glioma cells by sponging miR-15a/b-5p to upregulate the expression of HDGF and activating Wnt/beta-catenin signaling pathway. *INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES* 128:521-530. doi:10.1016/j.ijbiomac.2019.01.121

Zheng, Z., Liang, W., Milgrom, D.P., Zheng, Z., Schroder, P.M., Kong, N.S., Yang, C., Guo, Z., and He, X. 2014. Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: a meta-analysis of observational studies. *TRANSPLANTATION* 97:227-234. doi:10.1097/TP.0b013e3182a89383

Centers for Disease Control and Prevention. Liver and Intrahepatic Bile Ducts Cancers, United States—2006–2015. USCS data brief, no 5. Atlanta, GA: Centers for Disease Control and Prevention; 2018.

International Agency for Research on Cancer, World Health Organization. Cancer today (http://gco.iarc.fr/today/fact-sheets-cancers).

Zhou, Y., He, P., Xie, X., and Sun, C. 2019. Knockdown of SUMO1P3 represses tumor growth and invasion and enhances radio sensitivity in hepatocellular carcinoma. *MOLECULAR AND CELLULAR BIOCHEMISTRY* 450:125-134. 10.1007/s11010-018-3379-8
**Table 1** (on next page)

Clinical parameters of patients in the training set and testing set

BCLC stage: Barcelona Clinic Liver Cancer stage; Multinodular: Whether the tumor has multiple nodules.
Table 1. Clinical parameters of patients in the training set and testing set

| Variables          | Training set(n=103) | Testing set(n=100) | P value |
|--------------------|---------------------|--------------------|---------|
| Gender             |                     |                    |         |
| Female             | 13                  | 13                 |         |
| Male               | 90                  | 87                 | 1       |
| Age                |                     |                    |         |
| <60                | 80                  | 81                 |         |
| ≥60                | 23                  | 19                 | 0.68    |
| ALT                |                     |                    |         |
| <=50U/L            | 61                  | 54                 |         |
| >50U/L             | 42                  | 46                 | 0.542   |
| Main Tumor Size    |                     |                    |         |
| <=5 cm             | 68                  | 58                 |         |
| >5 cm              | 34                  | 42                 |         |
| NA                 | 1                   | 0                  | 0.26    |
| Multinodular       |                     |                    |         |
| NO                 | 86                  | 74                 |         |
| YES                | 17                  | 26                 | 0.138   |
| TNM stage          |                     |                    |         |
| I+II               | 82                  | 71                 |         |
| III                | 21                  | 27                 | 0.305   |
| NA                 | 0                   | 2                  |         |
| BCLC stage         |                     |                    |         |
| 0+A                | 83                  | 69                 |         |
| B+C                | 20                  | 29                 | 0.13    |
| NA                 | 0                   | 2                  |         |
| AFP                |                     |                    |         |
| <=300ng/ml         | 54                  | 52                 |         |
| >300ng/ml          | 46                  | 48                 | 0.887   |
| NA                 | 3                   | 0                  |         |

BCLC stage: Barcelona Clinic Liver Cancer stage; Multinodular: Whether the tumor has multiple nodules
Table 2 (on next page)

Five candidate lncRNAs screened by LASSO regression were inserted in multivariate
COX regression. Four lncRNAs with independent prognostic significance for overall
survival were screened out. Details of the four lncRNAs are as follows.

Correlation coefficient and Hazard ratio were the results of multivariate COX regression.
Table 2. Five candidate IncRNAs screened by LASSO regression were inserted in multivariate COX regression. Four IncRNAs with independent prognostic significance for overall survival were screened out.

| Gene name   | Ensemble ID  | coefficient | Hazard ratio | P value | Chromosome          |
|-------------|--------------|-------------|--------------|---------|---------------------|
| AC093797.   | ENSG00000    | -0.4818     | 0.6177       | 0.0003  | Chr4:185587909-185594004(+) |
| AL121748.1  | ENSG00000    | 0.4404      | 1.5534       | 0.038   | Chr10:33211277-33213805(+) |
| AL162231.4  | ENSG00000    | 1.2845      | 3.6129       | 0.0221  | Chr9:34661903-34666029(-) |
| POLR2J4     | ENSG00000    | -1.517      | 0.2194       | 0.0081  | Chr7:43940895-44019175(-) |

Correlation coefficient and Hazard ratio were the results of multivariate COX regression.
**Table 3** (on next page)

Stratified analysis of the overall survival of four-lncRNA signature in the training set and testing set.

*Statistically significant. Abbreviations: BCLC stage: Barcelona Clinic Liver Cancer stage; Multinodular: Whether the tumor has multiple nodules. HR, Hazard ratio; 95%CI, 95% confidence interval.
Table 3. Stratified analysis of the overall survival of four-lncRNA signature in the training set and testing set.

| Variable | Training set | | | Testing set | | |
|----------|--------------|---|---|--------------|---|---|
|          | Number (High/Lo) | HR (95%CI) | P value | Number (High/Lo) | HR (95%CI) | P value |
| Gender   |              |               |       |              |               |       |
| Female   | 6/7          | 3.939 (0.400) | 0.2   | 6/7          | 4.037 (0.360) | 0.22   |
|          |              | 9-37.96       |       |              | 5-44.68      |        |
| Male     | 45/45        | 3.603 (1.66)  | 0.0005 | 38/49        | 2.405 (1.31) | 0.0034 |
|          |              | 8-7.781       | *     |              | 2-4.408      | *      |
| Age      |              |               |       |              |               |       |
| <60      | 45/35        | 3.536 (1.51)  | 0.0019 | 34/47        | 2.412 (1.26) | 0.0056 |
|          |              | 2-8.27        | *     |              | 9-4.584      | *      |
| ≥60      | 6/17         | 4.253 (0.94)  | 0.059  | 10/9         | 7.153 (0.85) | 0.069  |
|          |              | 6-19.11       |       |              | 8-59.62      |        |
| ALT      |              |               |       |              |               |       |
| <=50U/L  | 27/34        | 2.985 (1.32)  | 0.0056 | 22/32        | 2.479 (1.04) | 0.033* |
|          |              | 5-6.726       | *     |              | 7-5.868      |        |
| >50U/L   | 24/18        | 10.87 (1.38)  | 0.0045 | 22/24        | 2.358 (1.05) | 0.032* |
|                          |       |       |       |       |       |
|--------------------------|-------|-------|-------|-------|-------|
|                          | 6-85.23) | * | 6-5.269) |       |       |
| Main Tumor Size          |       |       |       |       |       |
| <=5 cm                   | 32/36 | 5.949(1.96 | 0.0003 | 21/37 | 2.145(0.99 | 0.0523 |
|                          |       | 3-18.02) | 6* |       | 3-4.637) |       |
| >5 cm                    | 18/16 | 2.213(0.82 | 0.11 | 23/19 | 2.5(0.992- | 0.0519 |
|                          |       | 5-5.94) |       |       |       | 6.298) |
| Multinodular             |       |       |       |       |       |
| NO                       | 39/47 | 4.157(1.83 | 0.0002 | 30/44 | 3.017(1.47 | 0.0015 |
|                          |       | 4-9.419) | 1* |       | 2-6.183) | * |
| YES                      | 12/5  | 1.575(0.31 | 0.58 | 14/12 | 0.641(0.23 | 0.39 |
|                          |       | 6-7.857) |       |       | 1-1.777) |       |
| TNM stage                |       |       |       |       |       |
| I+II                     | 37/45 | 4.186(1.63 | 0.0012 | 24/47 | 2.779(1.33 | 0.0043 |
|                          |       | 3-10.73) | * |       | 7-5.778) | * |
| III                      | 14/7  | 1.778(0.55 | 0.33 | 19/8  | 1.454(0.50 | 0.49 |
|                          |       | 5-5.693) |       |       | 3-4.206) |       |
| BCLC stage               |       |       |       |       |       |
| 0+A                      | 36/47 | 4.728(1.85 | 0.0003 | 26/43 | 3.238(1.48 | 0.0019 |
|                          |       | 8-12.03) | 3* |       | 1-7.08) | * |
| B+C                      | 15/5  | 0.879(0.27 | 0.83 | 17/12 | 0.630(0.25 | 0.32 |
|                | 5-2.816)                                                                 | 2-1.575)                                                                 |
|----------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| **AFP**        |                                                                            |                                                                            |
| <=300ng/ml     | 21/33                                                                     | 17/35                                                                     |
|                | 3.944(1.44 0.0039)                                                       | 4.625(1.84 0.0003)                                                       |
|                | 6-10.76)                                                                  | *                                                                         |
| >300ng/ml      | 29/17                                                                      | 27/21                                                                     |
|                | 3.012(1.00 0.039*)                                                        | 1.438(0.65 0.36)                                                         |
| 1              | 4-9.033)                                                                  | 9-3.136)                                                                  |

*Statistically significant. Abbreviations: BCLC stage: Barcelona Clinic Liver Cancer stage; Multinodular: Whether the tumor has multiple nodules. HR, Hazard ratio; 95%CI, 95% confidence interval.
Table 4\textit{(on next page)}

Stratified analysis of the recurrence-free survival of four-LncRNA signature in the training set and testing set.

*Statistically significant. Abbreviations: BCLC stage: Barcelona Clinic Liver Cancer stage; Multinodular: Whether the tumor has multiple nodules. HR, Hazard ratio; 95%CI, 95% confidence interval.
**Table 4.** Stratified analysis of the recurrence-free survival of four-lncRNA signature in the training set and testing set.

| Variable | Training set | | | Testing set | | |
| --- | --- | --- | --- | --- | --- | --- |
| | Number | HR (95%CI) | P value | Number | HR (95%CI) | P value |
| Gender | | | | | | |
| Female | 6/7 | 5.765 (0.64 - 51.95) | 0.078 | 6/7 | 7.811 (0.80 - 76.15) | 0.077 |
| Male | 45/45 | 2.166 (1.21 - 3.854) | 0.0071* | 38/49 | 2.072 (1.22 - 3.508) | 0.0056* |
| Age | | | | | | |
| <60 | 45/35 | 2.34 (1.214 - 4.51) | 0.0089 | 34/47 | 1.954 (1.10 - 3.464) | 0.02* |
| ≥60 | 6/17 | 3.758 (1.14 - 12.29) | 0.019* | 9/9 | 4.428 (1.19 - 16.47) | 0.015* |
| ALT | | | | | | |
| <=50U/L | 27/34 | 2.164 (1.08 - 4.333) | 0.026* | 22/32 | 1.974 (0.94 - 4.115) | 0.064 |
| >50U/L | 24/18 | 2.852 (1.10 - 7-12.29) | 0.024* | 22/24 | 2.394 (1.17 - 23.9) | 0.013* |
|                     | Main Tumor Size | Multinodular     | TNM stage    | BCLC stage  |
|---------------------|-----------------|------------------|--------------|-------------|
| <=5 cm              | 2-7.379)        | 32/36            | 9-4.86)      |             |
|                     | 3.655(1.72       | 1.95(1.018       | 3.655(1.72   | 2.514(1.38  |
|                     | 0.0003)         | 0.04*            | 0.0003)      | 0.0018      |
|                     | 21/37           | 5-7.745)         | 21/37        | 39/47       |
|                     | *               | -3.735)          | 2.514(1.38   | 2.516(1.37  |
| >5 cm               | 1.324(0.57       | 2-4.573)         | 1.324(0.57   | 12/5        |
|                     | 0.51)           | *                | 0.51)        | 1.596(0.32  |
|                     | 23/19           | 9-6.199)         | 30/44        | 30/44       |
|                     | 1.324(0.57       | 1.324(0.57       | 1.324(0.57   | 1.658(0.63  |
|                     | 0.51)           | 0.51)            | 0.51)        | 0.3         |
| Multinodular        | 23/19           | 2.586(1.07       | 2.586(1.07   | 14/12       |
|                     | 0.028*          | 0.028*           | 0.028*       | 1.658(0.63  |
|                     | 9-6.199)        | 9-6.199)         | 9-6.199)     | 5-4.331)    |
| Multinodular        | 39/47           | 2.516(1.37       | 2.516(1.37   | 12/5        |
| Multinodular        | 0.0019*         | 0.0019*          | 0.0019*      | 1.658(0.63  |
| Multinodular        | 14/12           | 2.837(1.52       | 2.837(1.52   | 14/12       |
| Multinodular        | 0.00061         | 0.00061          | 0.00061      | 1.658(0.63  |
| Multinodular        | 19/8            | 4-5.282)         | 4-5.282)     | 14/12       |
| Multinodular        | *               | *                | *            | 1.658(0.63  |
| Multinodular        | 8-3.184)        | 8-3.184)         | 8-3.184)     | 5-4.331)    |
| Multinodular        | 15/5            | 2.671(1.41       | 2.671(1.41   | 15/5        |
| Multinodular        | 0.0018*         | 0.0018*          | 0.0018*      | 1.658(0.63  |
| Multinodular        | 5-5.104)        | 5-5.104)         | 5-5.104)     | 1.658(0.63  |
| Multinodular        | *               | *                | *            | 0.66        |
| Multinodular        | 17/12           | 1.608(0.66       | 1.608(0.66   | 17/12       |
| Multinodular        | 0.29            | 0.29             | 0.29         | 1.608(0.66  |
|   | 7-1.7) | 8-3.872) |
|---|---|---|
| AFP | <=300ng/ml | ml | >300ng/ml |
|   | 21/33 | 3-4.625) | 29/17 | 1-6.255) |
|   | 2.228(1.07 | 0.027* | 17/35 | 3.615(1.69 | 0.00042 |
|   | 2-7.724) | * | 27/21 | 1.426(0.70 | 0.32 |

*Statistically significant. Abbreviations: BCLC stage: Barcelona Clinic Liver Cancer stage; Multinodular: Whether the tumor has multiple nodules. HR, Hazard ratio; 95%CI, 95% confidence interval.
Figure 1

Analysis of flowchart

The flowchart indicates the exploration process and potential mechanism of cirrhotic HCC prognostic IncRNAs.
Raw data collected from GEO database

GSE14520 re-annotation (12096 mRNAs and 610 IncRNAs)

GSE14520:204 HCC
Randomly dividing into training set (n = 103) and testing set (n = 100)

Training set (n = 103)

Screening IncRNAs associated with OS (Univariate Cox regression)

LASSO

Four- IncRNA risk model for HCC OS and RFS (Multivariate Cox regression)

Validation in testing set (n = 100)

Kaplan-Meier curves

Functional enrichment in GSE14520 (n=204)

Stratification survival analysis in training set (n = 103) and testing set (n = 100)
The remaining lncRNAs were further selected using LASSO regression analysis, and cross-validation was used to select the penalty parameters.

(A) LASSO coefficient profiles of the 35 candidate lncRNAs. Ten-time cross-validation for penalty parameters selection in the LASSO model. (B) A vertical line is drawn at the value chosen by 10-fold cross-validation.
Figure 3

Prognostic efficiency of the prognostic risk scoring system for overall survival and recurrence-free survival.

(A) The four-lncRNA risk score distribution. (B) The heatmap of four lncRNAs gene expression in the high-risk and low-risk groups for the training set. (C) Overall survival status of patients in training set. (D) Recurrence status of patients in training set.
Figure 4

Prognostic significance evaluation of four-lncRNA signature for overall survival (OS) and recurrence-free survival (RFS) in the training set.

Kaplan-Meier analysis for high-risk and low-risk groups was used to analyze OS and RFS. (A) The survival curve of OS. (B) The survival curve of RFS. (C) ROC curve for prognosis prediction of the risk score model at 5 years of OS. (D) ROC curve at 5 years of RFS.
Figure 5

Prognostic performance of four-lncRNA signature on overall survival(OS) and recurrence-free survival(RFS) in the testing set.

Kaplan-Meier analysis for high-risk and low-risk groups was used to analyze overall survival and recurrence-free survival. (A) The survival curve of OS. (B) The survival curve of RFS. (C) ROC curve for prognosis prediction of the risk score model at 5 years of OS. (D) ROC curve at 5 years of RFS. (E) Overall survival status of patients in testing set. (F) Recurrence status of patients in testing set.
Figure 6

Kaplan-Meier curves of the overall survival for high-risk and low-risk patients with different clinical characteristics in training set and testing set.

Following clinical characteristics : (A) solitary tumor in training set. (B) solitary tumor in testing set. (C) TNM stage I-II in training set. (D) TNM stage I-II in testing set. (E) BCLC stage 0-A in training set. (F) BCLC stage 0-A in testing set.
Figure 7

Kaplan-Meier curves of the recurrence-free survival for high-risk and low-risk patients with different clinical characteristics in training set and testing set.

Following clinical characteristics: (A) solitary tumor in training set. (B) solitary tumor in testing set. (C) TNM stage I-II in training set. (D) TNM stage I-II in testing set. (E) BCLC stage 0-A in training set. (F) BCLC stage 0-A in testing set.
Figure 8

Functional enrichment analysis of four IncRNAs-associated protein-coding genes.

(A) Significantly enriched top 25 GO (gene ontology) terms. (B) Top 25 KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways.
